Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor
By A Mystery Man Writer
Description
Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.
Epidermal growth factor receptor-related signaling pathways and
Lapatinib and lapatinib plus trastuzumab therapy versus
Lapatinib and lapatinib plus trastuzumab therapy versus
Pharmaceuticals, Free Full-Text
Lapatinib: An Oral Dual Tyrosine Kinase Inhibitor for HER-2
Lapatinib and lapatinib plus trastuzumab therapy versus
Managing side effects of immune checkpoint inhibitors in breast
Lapatinib and lapatinib plus trastuzumab therapy versus
Association between efficacy and skin rash following treatment
Lapatinib and lapatinib plus trastuzumab therapy versus
Management algorithm for lapatinib- associated rash for nurses
Lapatinib and lapatinib plus trastuzumab therapy versus
Cutaneous toxicities from targeted therapies used in oncology
from
per adult (price varies by group size)